Vaccines Session Spotlight: Influenza Vaccines for Pandemic Preparedness and the Future and the World’s First Egg-Free Vaccine

Pandemic preparedness is a regulatory and industry effort. Today we feature two of the sessions at Vaccines Development and Production Summit.  You can  hear from the latest U.S. Department of Health and Human Services efforts from Keynote Presenter Robert C. Huebner, Ph.D., Acting Director, Influenza Division, HHS/ASPR/BARDA.  We'll also be joined by Manon M.J. Cox, President and CEO, Protein Sciences Corporation, who developed the  the novel technology Flublok.  It was also  the worlds’ first recombinant, highly purified, egg-free influenza vaccine and it successively navigated the regulatory pathway of the FDA.

The Vaccines Development and Production Summit will take place June 3-5, 2013 in Durham, North Carolina. For more information the featured sessions and the rest of the agenda, download the program.  If you'd like to join us, as a reader of this blog when you register to join us and mention code B13187SPX32, you'll save 20% off the standard rate.

Featured Sessions:

Development of New Influenza Vaccines for Pandemic Preparedness and the Future
Featured Speaker: Robert C. Huebner, Ph.D., Acting Director Influenza Division, HHS/ASPR/BARDA
About the presentation: Since 2004, BARDA has supported the nation’s pandemic preparedness and the technology use for seasonal and pandemic influenza vaccine production. This talk reviews the progress of the current BARDA programs and discusses future efforts to meet the nation’s needs for seasonal and pandemic influenza vaccines.


Flublok®: Developing the World’s First Recombinant, Highly Purified, Egg-Free Influenza Vaccine
Featured Speaker: Manon M.J. Cox, President and CEO, Protein Sciences Corporation
About the presentation:This presentation explores the novel manufacturing technology and regulatory pathway of Flublok, which the FDA regards as a technological advance in the manufacturing of an influenza vaccine. This keynote examines the departure from using the virus and eggs in production and how the process allows for the rapid production of large quantities of the influenza virus protein, hemagglutinin (HA), using a baculovirus expression system.

Share this article with your social network, just click below to share now!

Share |